Skip to main content
. 2016 Aug 25;22(5):436–443. doi: 10.5152/dir.2016.15430

Table 3.

Consistency test of included RCTs with the node-splitting method

Amputation
Comparison Direct effect Indirect effect Overall P
BA vs. DEB 0.54 (−0.81, 1.56) −1.30 (−4.59, 1.52) 0.35 (−1.01, 1.34) 0.23
BA vs. DES −0.46 (−1.85, 0.92) 0.25 (−1.50, 1.89) −0.23 (−1.19, 0.83) 0.50
BA vs. NDMS 0.67 (−0.21, 1.74) 0.71 (−1.37, 2.67) 0.66 (−0.16, 1.56) 0.98
DEB vs. DES 0.85 (−2.01, 4.36) −0.91 (−2.32, 0.78) −0.58 (−1.80, 1.07) 0.25
DES vs. NDMS 0.87 (−0.79, 2.77) 0.95 (−0.68, 2.45) 0.92 (−0.21, 1.96) 0.93

Restenosis
Comparison Direct effect Indirect effect Overall P
BA vs. DEB −0.98 (−2.77, 0.89) −0.08 (−3.36, 3.04) −0.78 (−2.26, 0.77) 0.59
BA vs. DES −0.94 (−3.43, 1.61) −1.90 (−3.68, −0.14) −1.56 (−3.01, −0.25) 0.48
BA vs. NDMS 0.01 (−1.46, 1.39) 0.34 (−2.35, 3.04) 0.08 (−1.11, 1.23) 0.78
DEB vs. DES −1.32 (−4.11, 1.45) −0.44 (−2.99, 1.92) −0.79 (−2.63, 0.85) 0.58
DES vs. NDMS 1.75 (0.20, 3.35) 1.41 (−1.07, 3.96) 1.64 (0.46, 2.91) 0.80

Technical success
Comparison Direct effect Indirect effect Overall P
BA vs. DEB 0.09 (−2.50, 2.65) 0.27 (−4.80, 4.96) 0.12 (−1.84, 2.22) 0.94
BA vs. DES 0.29 (−2.27, 2.96) −0.10 (−4.87, 4.59) 0.26 (−1.96, 2.30) 0.91
BA vs. NDMS 2.12 (−0.19, 5.50) 8.14 (−20.12, 37.90) 2.34 (−0.14, 5.94) 0.72
DEB vs. DES 0.28 (−3.99, 4.83) 0.03 (−3.42, 3.70) 0.13 (−2.47, 2.49) 0.94
DES vs. NDMS 11.65 (−12.53, 46.22) 2.03 (−1.15, 6.24) 2.14 (−0.97, 6.36) 0.46

TLR
Comparison Direct effect Indirect effect Overall P
BA vs. DEB −0.66 (−2.10, 0.72) 0.59 (−2.50, 3.58) −0.51 (−1.67, 0.71) 0.42
BA vs. DES 0.39 (−1.47, 2.12) −0.94 (−2.58, 0.50) −0.33 (−1.61, 0.77) 0.19
BA vs. NDMS 0.51 (−1.03, 2.10) 1.28 (−0.96, 3.26) 0.81 (−0.34, 1.96) 0.49
DEB vs. DES −0.70 (−3.44, 1.97) 0.49 (−1.60, 2.36) 0.18 (−1.40, 1.56) 0.42
DES vs. NDMS 1.31 (0.08, 2.67) 0.54 (−1.59, 3.01) 1.14 (0.19, 2.24) 0.49

Data are presented as relative effect (95% credible interval).

RCT, randomized controlled trial; BA, balloon angioplasty; DEB, drug-eluting balloon; DES, drug-eluting stent; NDMS, nondrug metal stent; TLR, target lesion revascularization.